BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Genprex Selects Andelyn Biosciences to Scale Up AAV Gene Therapy for Diabetes

Andelyn Biosciences, a leading contract development and manufacturing organization, announced that Genprex, Inc. has selected Andelyn to support scale-up m...

September 03, 2026 | News

Ascletis Doses First Patient in Global Phase III Programme for Oral GLP-1 Obesity Drug ASC30

- Expected to enroll approximately 4,600 participants with obesity or overweight across two pivotal trials (AURORA-1 and AURORA-2) in the U.S., Europe, and...

September 01, 2026 | News

SIBIONICS Showcases AI-Powered GS3 Glucose Monitoring, Advances Integrated Diabetes Care at Melbourne Congress

SIBIONICS showcased its sensor innovation and AI-powered glucose monitoring at the joint IDF-WPR, ADC and Metabolic Diseases 2026 congress, held in Melbour...

September 01, 2026 | News

South Korea’s Hanmi Pharm Licenses Obesity Drug HM17321 to Genentech in $2.3B Deal

HM17321, a proprietary UCN2 (urocortin-2) analog, is being developed as a treatment for chronic-weight management and associated conditions, including ob...

August 25, 2026 | News

Kodiak Sciences Enrols First Patients in Phase III ALTO Trial of KSI-501 for Diabetic Macular Edema

Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializin...

August 12, 2026 | News

Biocon Launches Interchangeable YESAFILI Biosimilar to EYLEA in the U.S.

Yesafili™ (aflibercept-jbvf) now available in the United States as an U.S. FDA-approved interchangeable biosimilar to EYLEA 2 mg Potential ...

August 06, 2026 | News

Ascletis Initiates Global Phase III Trial for Oral GLP-1 Obesity Drug ASC30

-Initiated global Phase III program for oral small molecule GLP-1, ASC30, which will enroll approximately 4,600 participants with obesity or overweight acr...

August 05, 2026 | News

Torrey Pines Medicine Raises Angel Funding to Advance Ultra-Long-Acting Peptide Therapies

Led by Lotus Lake Capital, the financing will accelerate the development of TPM004, a differentiated ultra-long-acting amylin/calcitonin receptor dual agon...

July 30, 2026 | News

APAC's Peptide-Capacity Gamble

For most of pharmaceutical history, the hard part was finding a molecule that worked. The GLP-1 class inverted that logic. The science arrived first &mdash...

July 09, 2026 | Analysis

Singapore Updates Wegovy Label to Include Higher-Dose Semaglutide Data Showing Up to 25% Weight Loss

Up to one in three participants on semaglutide 7.2 mg achieved at least 25% weight loss over 72 weeks Mean weight loss with semaglutide 7.2 mg reached 2...

July 09, 2026 | News

Ascletis Files Dual US INDs for Ultra-Long-Acting Obesity Therapies Targeting Amylin, GLP-1 and GIP Receptors

ASC36_35 FDC, a once-monthly subcutaneous (SQ) injection co-formulation of ASC36 and ASC35, is a potentially first-in-class drug candidate targeting thre...

July 07, 2026 | News

ALR Technologies Expands Diabetes Device Business with CGM Medical Acquisition

ALR Technologies SG Ltd ("ALRT" or the "Company") (OTC: ALRTF), the diabetes management company, announces it has entered into a Letter of Intent ("LOI") t...

July 02, 2026 | News

S-CELL Launches Next-Generation Synbiotic to Naturally Support GLP-1 Production for Metabolic Health

S-CELL, a premier innovator in cellular health and anti-aging biotechnology, today announced the launch of its advanced metabolic support synbiotic (Prebio...

June 29, 2026 | News

Lakewood Amedex Advances Nu 3 Bisphosphocin Candidate With Strong AMR Resistance Profile

Nu-3 represents a novel class of potent, fast-acting, broad-spectrum antimicrobials called Bisphosphocins® Lakewood-Amedex Biotherapeutics Inc., (NASD...

May 04, 2026 | News

Stay Connected